Compare ODC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | EYPT |
|---|---|---|
| Founded | 1941 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 1.5B |
| IPO Year | N/A | 2005 |
| Metric | ODC | EYPT |
|---|---|---|
| Price | $58.99 | $15.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 66.6K | ★ 920.8K |
| Earning Date | 03-10-2026 | 03-04-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $478,113,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.26 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $41.37 | $3.91 |
| 52 Week High | $69.76 | $19.11 |
| Indicator | ODC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 42.97 |
| Support Level | $47.51 | $14.50 |
| Resistance Level | $60.00 | $17.61 |
| Average True Range (ATR) | 1.68 | 1.08 |
| MACD | 1.06 | -0.22 |
| Stochastic Oscillator | 86.40 | 24.73 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.